Cagrilintide
Last checked 21 Oct 2026An experimental peptide being studied for weight management. It isn't approved in Australia.
- Also calledA long-acting amylin analogue
- Commonly discussed forWeight management, in clinical trials (evidence is limited)
- Lab reportsNot listed
Research products sold online aren't TGA approved.
In plain English
Cagrilintide is a long-acting version of amylin, a hormone made in the pancreas that's involved in fullness after eating. It's being studied in clinical trials, mostly in combination with semaglutide. It isn't approved by the TGA, and products sold online as research peptides are unapproved, with no check on what's inside. Safety over the long term is still being studied. Talk to your GP about approved options.